Ann: Imugene appoints Dr Jakob Dupont as Non-Executive Director, page-9

1) Contributions to development and approval of 10 Oncology drugs.
2) NASDAQ connections.
3) Collaboration with pharma partners.

IMU is lining up some heavy hitters - and the NASDAQ connection reflects some speculation on NASDAQ listing recently discussed on this forum.

Dr Dupont is an industry and academic drug development expert, specialising in oncology and other
therapeutic areas, with more than 20 years of experience. He has made major contributions to the
development and approval of ten oncology drugs and has orchestrated successful development programs
for numerous drugs.
Dr Dupont is currently the Global Head of Research and Development at NASDAQ-listed Atara
Biotherapeutics (NASDAQ: ATRA), where he oversees all research and development including three clinical
stage programs spanning Phase 1 through to Phase 3, and numerous pre-clinical programs. He also oversees
key collaborations with academic and pharma partners, holds leadership and guidance roles for various
teams within the business and acts as a spokesperson to investors and the Board of Directors.
Prior to Atara, Dr Dupont spent more than six years in various roles at Genentech/Hoffman-La Roche
including as Vice President, Global Head of Breast and GYN Cancer Development, in addition to a further five
years at Oncomed Pharmaceuticals as Senior Vice President and Chief Medical Officer.
Dr Dupont is currently an Independent Director at Apexigen (NASDAQ: APGN) and a Scientific Advisory Board
Member at AMBRX (NASDAQ: AMAM).